Ftse Mib
33.089,72
-0,23%
DAX
19.261,75
-0,22%
S&P 500
5.998,74
-0,38%
NASDAQ
19.060,48
-0,60%
Bitcoin
95.659,62
-0,33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CRISPR Therapeutics AG (CRSP) CRISPR Therapeutics AG (CRSP) Notizie

CRISPR Therapeutics AG

CRSP
51,00
1,69 (3,43%)
28 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/11/202414:30GLOBECRISPR Therapeutics to Present at the Jefferies London..
13/11/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202414:00GLOBECRISPR Therapeutics to Present at the Guggenheim Inaugural..
05/11/202415:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/11/202415:05EDGAR2Form 8-K - Current report
05/11/202415:01GLOBECRISPR Therapeutics Provides Business Update and Reports..
18/10/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/8/202400:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/8/202423:22EDGAR2Form S-3ASR - Automatic shelf registration statement of..
05/8/202422:54EDGAR2Form S-8 - Securities to be offered to employees in employee..
05/8/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202422:05EDGAR2Form 8-K - Current report
05/8/202422:01GLOBECRISPR Therapeutics Provides Business Update and Reports..
03/6/202414:06EDGAR2Form 8-K - Current report
31/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202422:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202414:00GLOBECRISPR Therapeutics to Participate in Upcoming Investor..
24/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202422:25EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/5/202414:14EDGAR2Form 8-K - Current report
23/5/202414:00GLOBECRISPR Therapeutics Strengthens Executive Leadership Team..
09/5/202414:30GLOBECRISPR Therapeutics to Present at the Bank of America..
08/5/202422:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:00GLOBECRISPR Therapeutics Provides Business Update and Reports..
08/5/202413:00GLOBECRISPR Therapeutics Highlights ASGCT Oral Presentation and..
22/4/202422:30GLOBECRISPR Therapeutics to Present Oral Presentation at the..
03/4/202414:00GLOBECRISPR Therapeutics to Present at the Annual Needham Virtual..
01/4/202414:00GLOBECRISPR Therapeutics to Present at the American Society of..
13/3/202413:30GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
21/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202413:50EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21/2/202413:45EDGAR2Form 8-K - Current report
21/2/202413:30GLOBECRISPR Therapeutics Provides Business Update and Reports..
16/2/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:30EDGAR2Form 144 - Report of proposed sale of securities
15/2/202414:30GLOBECRISPR Therapeutics to Present at the Citi 2024 Virtual..
13/2/202414:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202414:30GLOBECRISPR Therapeutics Announces $280 Million Registered Direct..
13/2/202412:30EDGAR2Form 8-K - Current report
13/2/202408:30GLOBEEuropean Commission Approves First CRISPR/Cas9 Gene-Edited..
31/1/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:08EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 49,70 Min: 49,6555 Max: 50,97
Chiusura: 49,31

La tua Cronologia

NASDAQ
CRSP
CRISPR Therapeutics
BIT
UC17A6
Unicredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network